News & Updates

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021 by

The anti-PD-1 monoclonal antibody sintilimab outperformed docetaxel as second-line treatment for advanced and metastatic squamous non-small-cell lung cancer (NSCLC), according to the results of the phase III ORIENT-3 trial presented at AACR 2021.

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021

Real-world study affirms benefit of mepolizumab in severe eosinophilic asthma

12 May 2021

Interleukin 5 (IL-5) inhibition with mepolizumab appears to improve asthma control, cutting the incidences of exacerbations and hospitalizations, in patients with severe eosinophilic asthma treated in a real-world setting, a study reports.

Real-world study affirms benefit of mepolizumab in severe eosinophilic asthma

12 May 2021

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

11 May 2021 by

About 50 percent of children who develop Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) present with neurological features, according to a small study presented at AAN 2021.

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

11 May 2021

Hypertension after COVID-19 vaccine? Swiss study

11 May 2021 by

A very small proportion of people developed stage III hypertension within minutes after getting an mRNA-based COVID-19 vaccine, reports a case series study from Switzerland.

Hypertension after COVID-19 vaccine? Swiss study

11 May 2021

Tocilizumab, sarilumab may improve COVID-19 outcomes

10 May 2021 by

Two interleukin-6 receptor antagonists – tocilizumab and sarilumab – fared better than standard of care in improving survival and speeding up recovery in critically ill patients with COVID-19, according to findings of the REMAP-CAP* trial.

Tocilizumab, sarilumab may improve COVID-19 outcomes

10 May 2021

Do portable air filters eliminate bacteria, virus indoors?

09 May 2021

Despite claims, there appears to be no solid evidence base that the modern, commercially available portable air filters can remove viruses or bacteria from indoor air or that they can prevent respiratory infections, a recent systematic review has found.

Do portable air filters eliminate bacteria, virus indoors?

09 May 2021

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

07 May 2021 by

A regimen containing bedaquiline appears to be safe in the treatment of patients with rifampin-resistant tuberculosis, with severe prolongation of the QT interval occurring infrequently and requiring no permanent discontinuation of therapy, as reported in a recent study.

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

07 May 2021

COVID-19 single-shot vax cleared for use again

06 May 2021 by

Johnson & Johnson’s single-shot COVID-19 vaccine is safe for use in individuals 18 years of age and older, but it will likely come with a warning label, says the US Centers for Disease Control and Prevention (CDC).

COVID-19 single-shot vax cleared for use again

06 May 2021

Pneumonia hospitalization a risk factor for cardiac events

06 May 2021

Hospitalization for pneumonia contributes to an increased risk of ischaemic cardiovascular disease in the short and long term among middle-aged and older adults, a study has found.

Pneumonia hospitalization a risk factor for cardiac events

06 May 2021

Single-dose BNT162b2 COVID-19 vaccine inadequate in cancer patients

06 May 2021 by

One dose of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine yields poor efficacy in patients with solid or haematological cancer, but immunogenicity increases significantly in those with solid cancer following a second dose given on day 21 after the first dose, a prospective observational study has shown.

Single-dose BNT162b2 COVID-19 vaccine inadequate in cancer patients

06 May 2021

News & Updates

Filter by Specialty:

Specialty:

Sintilimab shows potential as second-line treatment option for squamous NSCLC

Sintilimab shows potential as second-line treatment option for squamous NSCLC

Real-world study affirms benefit of mepolizumab in severe eosinophilic asthma

Real-world study affirms benefit of mepolizumab in severe eosinophilic asthma

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

Hypertension after COVID-19 vaccine? Swiss study

Hypertension after COVID-19 vaccine? Swiss study

Tocilizumab, sarilumab may improve COVID-19 outcomes

Tocilizumab, sarilumab may improve COVID-19 outcomes

Do portable air filters eliminate bacteria, virus indoors?

Do portable air filters eliminate bacteria, virus indoors?

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

COVID-19 single-shot vax cleared for use again

COVID-19 single-shot vax cleared for use again

Pneumonia hospitalization a risk factor for cardiac events

Pneumonia hospitalization a risk factor for cardiac events

Single-dose BNT162b2 COVID-19 vaccine inadequate in cancer patients

Single-dose BNT162b2 COVID-19 vaccine inadequate in cancer patients